| Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis E Vilar-Gomez, Y Martinez-Perez, L Calzadilla-Bertot, A Torres-Gonzalez, ... Gastroenterology 149 (2), 367-378. e5, 2015 | 2184 | 2015 |
| Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study E Vilar-Gomez, L Calzadilla-Bertot, VWS Wong, M Castellanos, ... Gastroenterology 155 (2), 443-457. e17, 2018 | 681 | 2018 |
| Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers E Vilar-Gomez, N Chalasani Journal of hepatology 68 (2), 305-315, 2018 | 598 | 2018 |
| Vitamin E improves transplant‐free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis E Vilar‐Gomez, R Vuppalanchi, S Gawrieh, M Ghabril, R Saxena, ... Hepatology 71 (2), 495-509, 2020 | 163 | 2020 |
| High‐quality diet, physical activity, and college education are associated with low risk of NAFLD among the US population E Vilar‐Gomez, LD Nephew, R Vuppalanchi, S Gawrieh, A Mladenovic, ... Hepatology 75 (6), 1491-1506, 2022 | 141 | 2022 |
| Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease E Vilar Gomez, A Rodriguez De Miranda, B Gra Oramas, E Arus Soler, ... Alimentary pharmacology & therapeutics 30 (10), 999-1009, 2009 | 134 | 2009 |
| The effects of metabolic status on non‐alcoholic fatty liver disease‐related outcomes, beyond the presence of obesity J Ampuero, R Aller, R Gallego‐Durán, JM Banales, J Crespo, ... Alimentary pharmacology & therapeutics 48 (11-12), 1260-1270, 2018 | 110 | 2018 |
| Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline R Aller, C Fernandez-Rodriguez, O Lo Iacono, R Banares, J Abad, ... Gastroenterología y Hepatología (English Edition) 41 (5), 328-349, 2018 | 108 | 2018 |
| The natural history of compensated HCV-related cirrhosis: a prospective long-term study EV Gomez, YS Rodriguez, LC Bertot, AT Gonzalez, YM Perez, EA Soler, ... Journal of hepatology 58 (3), 434-444, 2013 | 102 | 2013 |
| Screening for nonalcoholic fatty liver disease in persons with type 2 diabetes in the United States is cost-effective: a comprehensive cost-utility analysis M Noureddin, C Jones, N Alkhouri, EV Gomez, DT Dieterich, ME Rinella, ... Gastroenterology 159 (5), 1985-1987. e4, 2020 | 98 | 2020 |
| Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention E Vilar‐Gomez, A Yasells‐Garcia, Y Martinez‐Perez, L Calzadilla‐Bertot, ... Hepatology 63 (6), 1875-1887, 2016 | 75 | 2016 |
| Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease JP Arab, M Dirchwolf, MR Álvares-da-Silva, F Barrera, C Benítez, ... Annals of Hepatology 19 (6), 674-690, 2020 | 72 | 2020 |
| Improvement in liver histology due to lifestyle modification is independently associated with improved kidney function in patients with non‐alcoholic steatohepatitis E Vilar‐Gomez, L Calzadilla‐Bertot, SL Friedman, B Gra‐Oramas, ... Alimentary pharmacology & therapeutics 45 (2), 332-344, 2017 | 70 | 2017 |
| Long‐term metformin use may improve clinical outcomes in diabetic patients with non‐alcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis E Vilar‐Gomez, R Vuppalanchi, AP Desai, S Gawrieh, M Ghabril, ... Alimentary Pharmacology & Therapeutics 50 (3), 317-328, 2019 | 69 | 2019 |
| Antioxidant and immunomodulatory effects of Viusid in patients with chronic hepatitis C EV Gomez, YM Perez, HV Sanchez, GR Forment, EA Soler, LC Bertot, ... World journal of gastroenterology: WJG 16 (21), 2638, 2010 | 68 | 2010 |
| Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy‐proven NASH E Vilar‐Gomez, L Calzadilla‐Bertot, SL Friedman, B Gra‐Oramas, ... Liver International 37 (12), 1887-1896, 2017 | 63 | 2017 |
| Type 2 diabetes and metformin use associate with outcomes of patients with nonalcoholic steatohepatitis–related, Child–Pugh A cirrhosis E Vilar-Gomez, L Calzadilla-Bertot, VWS Wong, M Castellanos, ... Clinical Gastroenterology and Hepatology 19 (1), 136-145. e6, 2021 | 60 | 2021 |
| Geographical similarity and differences in the burden and genetic predisposition of NAFLD TCF Yip, E Vilar‐Gomez, S Petta, Y Yilmaz, GLH Wong, LA Adams, ... Hepatology 77 (4), 1404-1427, 2023 | 59 | 2023 |
| Cost effectiveness of different strategies for detecting cirrhosis in patients with nonalcoholic fatty liver disease based on United States health care system E Vilar-Gomez, Z Lou, N Kong, R Vuppalanchi, TF Imperiale, N Chalasani Clinical Gastroenterology and Hepatology 18 (10), 2305-2314. e12, 2020 | 50 | 2020 |
| Impaired glucose metabolism increases risk of hepatic decompensation and death in patients with compensated hepatitis C virus-related cirrhosis L Calzadilla-Bertot, E Vilar-Gomez, A Torres-Gonzalez, M Socias-Lopez, ... Digestive and Liver Disease 48 (3), 283-290, 2016 | 47 | 2016 |
